Results 161 to 170 of about 2,674,072 (303)

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, EarlyView.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

A Role of the Bile Salt Receptor FXR in Atherosclerosis

, 2010
This study reviews current insights into the role of bile salts and bile salt receptors on the progression and regression of atherosclerosis. Bile salts have emerged as important modifiers of lipid and energy metabolism.
Albert K. Groen, Hageman, Jurre, Herrema, H.J., Folkert Kuipers, Hageman, J., Kuipers, Folkert, Herrema, Hilde, Hilde Herrema, Kuipers, Folkert; id_orcid, Groen, A.K., Kuipers, F., Groen, Albert K., Jurre Hageman   +12 more
core   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, EarlyView.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

A case of maturity‐onset diabetes of the young with a pathogenic HNF1A variant and a coexisting NEUROD1 variant

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Maturity‐onset diabetes of the young (MODY) accounts for at least 1%–5% of diabetes cases and is usually caused by single gene variants. Accurate diagnosis of MODY is important for effective management, especially in young individuals who are lean and lack islet autoantibodies.
Tomofumi Takayoshi, Yushi Hirota, Kenji Sugawara, Aki Sugano, Mika Ohta, Takehito Takeuchi, Akane Yamamoto, Wataru Satake, Yutaka Takaoka, Wataru Ogawa   +9 more
wiley   +1 more source

Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

International Journal of General Medicine, 2013
John Gerich Department of Medicine, Endocrine/Metabolism Division, University of Rochester School of Medicine, Rochester, NY, USA Abstract: Postprandial plasma glucose concentrations are an important contributor to glycemic control.
Gerich J
doaj